Amgen AMGN Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $37.22B+1.3% | $36.75B+2.2% | $35.97B+3.0% | $34.92B+2.3% | $34.13B+2.1% | ||
| $11.81B-1.9% | $12.04B-1.1% | $12.17B-1.8% | $12.4B-1.8% | $12.63B-1.8% | ||
| $25.41B+2.8% | $24.71B+3.8% | $23.8B+5.7% | $22.52B+4.7% | $21.5B+4.5% | ||
| 68.3%+1.0pp | 67.2%+1.1pp | 66.2%+1.7pp | 64.5%+1.5pp | 63%+1.5pp | ||
| $7.51B+3.2% | $7.27B+6.1% | $6.85B+7.0% | $6.4B+4.9% | $6.11B+2.4% | ||
| $6.97B-1.2% | $7.05B+1.1% | $6.98B+1.4% | $6.88B-1.3% | $6.98B-1.7% | ||
| $4.9B-5.2% | $5.17B-4.9% | $5.43B-1.6% | $5.52B-1.1% | $5.58B-0.2% | ||
| $26.65B-3.7% | $27.67B+1.4% | $27.3B+2.2% | $26.73B+0.2% | $26.68B+2.0% | ||
| $10.57B+16.4% | $9.08B+4.7% | $8.67B+5.8% | $8.19B+10.0% | $7.45B+2.6% | ||
| 28.4%+3.7pp | 24.7%+0.6pp | 24.1%+0.6pp | 23.5%+1.6pp | 21.8%+0.1pp | ||
| $2.69B-2.4% | $2.76B-3.3% | $2.85B-3.1% | $2.94B-3.7% | $3.05B-3.2% | ||
| —— | —— | —— | —— | —— | ||
| $9.09B+1.2% | $8.98B+8.9% | $8.24B+11.0% | $7.42B+11.6% | $6.65B+44.3% | ||
| $1.29B+1.7% | $1.27B+2.1% | $1.24B+53.9% | $805M+12.3% | $717M+38.2% | ||
| $7.8B+1.2% | $7.71B+10.1% | $7.01B+5.8% | $6.62B+11.6% | $5.93B+45.1% | ||
| 21%0.0pp | 21%+1.5pp | 19.5%+0.5pp | 19%+1.6pp | 17.4%+5.1pp | ||
| $14.38+1.0% | $14.24+10.0% | $12.94+5.8% | $12.23+11.6% | $10.96+45.2% | ||
| $14.48+1.0% | $14.33+10.0% | $13.03+5.8% | $12.32+11.5% | $11.05+45.0% | ||
| 2.2B+0.1% | 2.2B0.0% | 2.2B0.0% | 2.2B0.0% | 2.2B+0.2% | ||
| 2.2B+0.1% | 2.2B0.0% | 2.2B0.0% | 2.2B0.0% | 2.1B+0.1% | ||
| —— | —— | —— | —— | $891M+460% | ||
| -$132M+11.4% | -$149M-207% | $139M— | —— | —— | ||
| —— | —— | —— | —— | $1.65B+1,138% | ||
| -$647M+10.3% | -$721M+30.4% | -$1.04B+7.2% | -$1.12B-3.6% | -$1.08B+12.3% | ||
| —— | —— | —— | —— | —— | ||
| $1.18B-59.4% | $2.9B+115% | $1.35B-20.2% | $1.69B— | —— | ||
| —— | —— | —— | —— | —— | ||
| $414M-17.0% | $499M+4.4% | $478M+18.6% | $403M+48.2% | $272M+196% | ||
| -$616M+30.5% | -$886M+18.7% | -$1.09B+28.8% | -$1.53B+24.0% | -$2.01B+20.5% | ||
| $312M+0.3% | $311M— | —— | —— | —— | ||
| $1.06B-16.5% | $1.27B+80.0% | $704M-2.2% | $720M-5.8% | $764M+17.2% | ||
| -$161M+1.8% | -$164M— | —— | —— | —— | ||
| —— | —— | $2.96B+9.4% | $2.7B+35.3% | $2B+67.2% | ||
| $2.69B-2.4% | $2.76B-3.3% | $2.85B-3.1% | $2.94B-3.7% | $3.05B-3.2% | ||
| -$5.32B+51.0% | -$10.86B+1.6% | -$11.04B+6.7% | -$11.84B-0.2% | -$11.81B-25.5% | ||
| -$2.21B-13.8% | -$1.94B-17.6% | -$1.65B-14.1% | -$1.45B-13.5% | -$1.28B-22.0% | ||
| $10.76B+8.0% | $9.96B-24.1% | $13.13B+9.3% | $12.01B-1.5% | $12.19B+6.1% | ||
| -$132M+11.4% | -$149M-207% | $139M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $5.2B+1.5% | $5.12B+1.5% | $5.05B+1.4% | $4.97B+1.4% | $4.9B+1.5% | ||
| $2.16B+16.2% | $1.86B+17.1% | $1.59B+12.7% | $1.41B+10.3% | $1.28B+16.5% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | -$121M-75.4% | -$69M+47.7% | ||
| $3.33B-33.3% | $5B0.0% | $5B-12.3% | $5.7B-6.6% | $6.1B+69.4% | ||
| $7.51B+3.2% | $7.27B+6.1% | $6.85B+7.0% | $6.4B+4.9% | $6.11B+2.4% | ||
| $37.22B+1.3% | $36.75B+2.2% | $35.97B+3.0% | $34.92B+2.3% | $34.13B+2.1% | ||
| $484M-2.0% | $494M-1.8% | $503M-1.8% | $512M0.0% | $512M-3.4% | ||
| $15.46B+8.5% | $14.25B+1.0% | $14.1B+2.8% | $13.71B+5.3% | $13.03B+1.4% | ||
| 41.5%+2.8pp | 38.8%-0.4pp | 39.2%-0.1pp | 39.3%+1.1pp | 38.2%-0.3pp | ||
| $10.57B+16.4% | $9.08B+4.7% | $8.67B+5.8% | $8.19B+10.0% | $7.45B+2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amgen's revenue?
- Amgen (AMGN) generated $37.2B in revenue over the trailing twelve months, up 9.1% year over year.
- Is Amgen profitable?
- Amgen reported $7.8B in net income over the trailing twelve months, a 21.0% net margin.
- What are Amgen's profit margins?
- Gross margin is 68.3% and operating margin is 28.4%, with a 21.0% net margin.
- What is Amgen's earnings per share?
- Amgen's diluted EPS over the trailing twelve months is $14.38.
- Where does Amgen's income statement data come from?
- Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
